Advanced search
Publication Cover
Pathology and Laboratory Medicine International Volume 9, 2017 - Issue
Submit an article Journal homepage
63
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Different expression of MIB1 in primary site of non-Hodgkin lymphoma and its bone marrow deposits, a pilot study

Jozef Malysz1 Department of Pathology, Penn State Milton S Hershey Medical Center, Hershey, PA, USACorrespondence[email protected]
,
Juanita J Evans2 Department of Pathology, St. John Heath – Providence, Southfield, MI, USA
,
Malcolm Acon-Laws3 Laboratorio de Patologia Hospital Cima, San Jose, Costa Rica
,
Michael G Bayerl1 Department of Pathology, Penn State Milton S Hershey Medical Center, Hershey, PA, USA
&
Michael H Creer1 Department of Pathology, Penn State Milton S Hershey Medical Center, Hershey, PA, USA
Pages 31-35 | Published online: 27 Feb 2017

References

  • Veronese SM, Maisano C, Scibilia J. Comparative prognostic value of Ki67 and MIB1proliferation indices in breast cancer. Anticancer Res. 1995;15(6B):2717–2722.
  • Broyde A, Boycov O, Strenov Y, et al. Role and prognostic significance of the ki-67 index in non-Hodgkin’s lymphoma. Am J Hematol. 2009;84:338–343.
  • Hasselblom S, Ridell B, Sigurdardottir M, et al. Low rather than high ki-67 protein expression is an adverse prognostic factor in diffuse large b-cell lymphoma. Leuk Lymphoma. 2008;49:1501–1509.
  • Yoon D, Choi D, Ahn H, et al. Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. Eur J Haematol. 2010;85:149–157.
  • Jovanovic M, Jakovic L, Bogdanovic A, et al. Poor outcome in patients with diffuse large b-cell lymphoma is associated with high percentage of bcl-2 and ki-67 positive tumor cells. Vojnosanit Pregl. 2009;66:738–743.
  • Gaudio F, Giordano A, Perrone T, et al. High ki-67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large b cell lymphoma before and after the introduction of rituximab. Acta Haematol. 2011;126:44–51.
  • Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large b-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011;117:7070–7078.
  • Ali A, Morgen E, Geddie W, et al. Classifying b-cell non-Hodgkin lymphoma by using MIB-1 proliferative index in fine-needle aspirates. Cancer Cytopathol. 2010;118:166–172.
  • EnVision™ G|2 Doublestain System, Rabbit/Mouse (DAB+/Permanent Red) Code K5361 2nd edition/. Available from: http://www.dako.com/us/ar49/p235046/prod_products.htm
  • Monoclonal Mouse Anti-Human Ki-67 Antigen Clone MIB-1 Code M7240 (specification sheet 104980-004) Dako Agilent Technology Company. Available from: http://www.dako.com/us/ar38/p104960/prod_products.htm. Accessed August 22, 2016.
  • Kremer M, Spitzer M, Mandl-Weber S, et al. Discordant bone marrow involvement in diffuse large b-cell lymphoma: comparative molecular analysis reveals a heterogeneous group of disorders. Lab Invest. 2003;83:107–114.
  • Kalogeraki A, Tzardi M, Panagiotides I, et al. MIB1 (Ki-67) expression in non-Hodgkin lymphomas. Anticancer Res. 1997;17:487–491.
  • Shin S, Sheibani K, Kezirian J, et al. Immunoarchitecture of normal bonemarrow: a study of frozen and fixed tissue sections. Hum Pathol. 1992;23:686–694.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.